Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography

YIERPAN Aishan; Gao Feng

doi:10.3969/j.issn.1001-5256.2016.01.022

Volume 32 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(1): 119-122

PDF( 1489 KB)

Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography

DOI: 10.3969/j.issn.1001-5256.2016.01.022

Department of Gastroenterology,The People' s Hospital of Xinjiang Uygur Autonomous Region

Received Date: 2015-05-11
Published Date: 2016-01-20

Abstract

Abstract

Objective To investigate the risk factors for the development of post- endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia( PEPH) after endoscopic retrograde cholangiopancreatography( ERCP). Methods The clinical data of 233 patients who underwent therapeutic ERCP from January 2012 to December 2014 in our hospital and met the inclusion criteria were analyzed retrospectively. Basic information including age,sex,drinking history,single stone,triglyceride,and nationality was extracted,and detailed information on intraoperative procedure,intraoperative diagnosis,and complications for ERCP was carefully recorded. Chi- square test was applied for comparison of categorical data between groups,and Logistic regression analysis were applied to determine the risk factors for the development of PEPH. Results The incidence of PEPH was 26. 6%( 62 /233). Univariate analysis showed that female sex( χ2= 3. 320,P= 0. 045),drinking history( χ2= 6. 108,P = 0. 010),common bile duct stenosis( χ2= 5. 767,P = 0. 012),single stone( χ2= 9. 121,P= 0. 020),juxta- ampullary duodenal diverticula( χ2= 28. 170,P < 0. 001),and abnormal triglyceride( χ2= 54. 717,P < 0. 001) might be the risk factors for PEPH,and these factors differed significantly between the two groups. Multivariate analysis showed that female sex( OR = 1. 616,P = 0. 025) drinking history( OR = 2. 360,P = 0. 010),common bile duct stenosis( OR = 2. 163,P = 0. 012),juxta- ampullary duodenal diverticula( OR = 5. 502,P < 0. 001),and abnormal triglyceride( OR = 12. 924,P < 0. 001) were independent risk factors for PEPH. Conclusion Female sex,drinking history,common bile duct stenosis,juxta- ampullary duodenal diverticula,and abnormal triglyceride are independent risk factors for PEPH,and targeted preventive measures for such high- risk populations can effectively reduce the incidence of PEPH.
- hyperamylasemia,
- pancreatitis,
- cholangiopancreatgraphy,endoscopic retrograde,
- risk factors

FullText(HTML)

References(15)

References

[1]JIA YL,JIANG H,HAN Z,et al.Clinical research on the bleeding in ERCP and EST[J].Chin J Clin Pharmacol Ther,2014,19(4):450-453.(in Chinese)贾玉良,姜华,韩真,等.ERCP与EST并发出血的相关临床研究[J].中国临床药理学与治疗学,2014,19(4):450-453.

[2]YU L,DENG T,ZHAN YJ,et al.The clinical value of ENBD in the prevention of post-ERCP pancreatitis and hyperamylasemia in patients with common bile duct stones[J].Chin J Gastroenterol Hepatol,2012,21(4):316-318.(in Chinese)余璐,邓涛,占义军,等.ENBD预防胆总管结石ERCP术后急性胰腺炎及高淀粉酶血症的临床价值[J].胃肠病学和肝病学杂志,2012,21(4):316-318.

[3]LI X,MENG W,ZHANG L,et al.Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis:a retrospective analysis of 7,168 cases[J].Pancreatology,2011,11(3):399-405.

[4]TUENNEMANN J,MSSNER J,BEER S.Acute pancreatitis:guideline-based diagnosis and treatment[J].Internist(Berl),2014,55(9):1045-1056.

[5]DING BJ,LI S,LIU C,et al.The value of preoperative MRCP on the diagnosis of CBD after cholecystectomy before operating ERCP:an analysis of 139 cases[J].Chin J Pract Intern Med,2015,35(5):449-450.(in Chinese)丁百静,李生,刘充,等.ERCP术前经磁共振胰胆管造影对胆囊切除术后胆总管结石139例诊断价值探讨[J].中国实用内科杂志,2015,35(5):449-450.

[6]SHAH TU,LIDDLE R,BRANCH MS,et al.Pilot study of aprepitant for pr evention of post-ERCP pancreatitis in high risk patients:a phaseⅡrandomized,double-blind placebo controlled trial[J].JOP,2012,13(2):514-518.

[7]WANG P,LI ZS,LIU F,et al.Risk factors for ERCP-related complications:a prospective multicenter study[J].Am J Gastroenterol,2009,104(7):31-40.

[8]TSUJINO T,KOMATSU Y,ISAYAMA H,et al.Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography:a randomized,controlled trial[J].Clin Gastroenterol Hepatol,2005,3(1):376-383.

[9]ELMUNZER BJ,SCHEIMAN JM,LEHMAN GA,et al.A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis[J].N Engl J Med,2012,366(11):1414-1422.

[10]KOBAYASHI Y,KANEMITU T,KAMOTO A,et al.Painless acute pancreatitis associated with sorafenib treatment:a case report[J].Med Oncol,2011,28(3):463-465.

[11]FREEMAN LD,KRIO JA,NDSON VB,et al.Risk factors of post-ERCP pancreatitis:a pmspective,muhicenteraudypl[J].Gastrintesf Eudose,2001,54(4):425-434.

[12]WANG P,LI ZS,LIU F,et al.Risk factors for ERCP-related complications:a prospective multicenter study[J].Am J Gastroentero,2009,104(1):31-40.

[13]CHOUDHARY A,BECHTOLD ML,ARIF M,et al.Pancreatic stents for prophylaxis against post-ERCP pancreatitis:a meta-analysis and systematic review[J].Gastrointest Endosc,2011,73(4):275-282.

[14]LEGHARI A,GHAZANFAR S,QURESHI S,et al.Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centr[J].J Coll Physicians Surg Pak,2013,23(9):620-624.

[15]CHEN JJ,WANG XM,LIU XQ,et al.Risk factors for post-ERCP pancreatitis:a systematic review of clinical trials with a large sample size in the past 10 years[J].Eur J Med Res,2014,19(26):1-7.

Relative Articles

[1]	Wenyu ZHAO, Yan FU, Yajiao DUAN, Juan TANG, Jing NI. Risk factors， diagnosis and treatment of perforation after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2025, 41(3): 580-587. doi: 10.12449/JCH250329
[2]	Lina QI, Ping CHEN. Recurrent hyperlipidemic acute pancreatitis： Etiology and prevention and treatment strategies[J]. Journal of Clinical Hepatology, 2024, 40(10): 2109-2115. doi: 10.12449/JCH241030
[3]	Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522
[4]	Chen XU, Wei YANG, Jie GU, Weizhong ZHOU, Haibin SHI. Incidence rates of hyperamylasemia and acute pancreatitis after percutaneous transhepatic biliary stenting and related risk factors[J]. Journal of Clinical Hepatology, 2021, 37(4): 882-887. doi: 10.3969/j.issn.1001-5256.2021.04.031
[5]	Ma Min, Zhou ZhongYin. A comparative analysis of acute pancreatitis and hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2020, 36(2): 395-398. doi: 10.3969/j.issn.1001-5256.2020.02.033
[6]	Chinese Digestive Endoscopist Committee, Chinese Endoscopist Association, Chinese Physicians′Association, Pancreatic Disease Committee, Chinese Physicians′Association. Expert consensus on perioperative medication for endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(12): 2555-2562. doi: 10.3969/j.issn.1001-5256.2018.12.010
[7]	ERCP group, Chinese Society of Digestive Endoscopology, Biliopancreatic group, Chinese Association of Gastroenterologist and Hepatologist, Na- tional Clinical Ｒesearch Center for Digestive Diseases. Chinese Guidelines for ERCP(2018)[J]. Journal of Clinical Hepatology, 2018, 34(12): 2537-2554. doi: 10.3969/j.issn.1001-5256.2018.12.009
[8]	Zhang WeiFeng, Li JiaSu, Liu Feng, Cheng YiFeng, Shen Peng. Research advances in the prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(3): 658-662. doi: 10.3969/j.issn.1001-5256.2018.03.049
[9]	Wang XiangPing, Pan YangLin, Guo XueGang. Advances in endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(3): 473-481. doi: 10.3969/j.issn.1001-5256.2018.03.004
[10]	Hu WeiLin. Risk factors for hypertriglyceridemia-induced acute pancreatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1518-1521. doi: 10.3969/j.issn.1001-5256.2017.08.022
[11]	Li Lu, Wei HongCheng, Feng ShuFen. Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(1): 110-115. doi: 10.3969/j.issn.1001-5256.2017.01.024
[12]	Wang Ai, Zhao LiJin. Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(1): 184-187. doi: 10.3969/j.issn.1001-5256.2017.01.043
[13]	Wang QunRu, Zhang Yong, Mou Dong, Chen BeiJin, Ni Hua, Gao Hui. Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(5): 896-898. doi: 10.3969/j.issn.1001-5256.2017.05.021
[14]	Wang ChunQiu, Ma YingCai, Zhu ZhiYong, Yuan Ling. Risk factors for recurrence of common bile duct stones after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(2): 297-299. doi: 10.3969/j.issn.1001-5256.2017.02.019
[15]	Bi RongXin, Guo QuanZhou, Xue ZhiGuang, Hou ZhiQiang. Analysis of incidence and risk factors for ERCP-related adverse events in patients with primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 189-192. doi: 10.3969/j.issn.1001-5256.2015.02.011
[16]	Li XiaoQing, Qian JiaMing. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Updated June 2014[J]. Journal of Clinical Hepatology, 2014, 30(12): 1236-1239. doi: 10.3969/j.issn.1001-5256.2014.12.002
[17]	Zhang RuoYan, Du XiaoHong, Wang Meng, Ye JunFeng, Jin GuoXing, Wang GuangYi. Severe thrombocytopenia in AOSC after ERCP: a report of one case[J]. Journal of Clinical Hepatology, 2014, 30(4): 373-374. doi: 10.3969/j.issn.1001-5256.2014.04.022
[18]	Wu JuShan, Li Lei, Song YanMing, Feng Li, Li Bing. Comparative study on safety of endoscopic retrograde cholangiopancreatography in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1267-1271. doi: 10.3969/j.issn.1001-5256.2014.12.009
[19]	Zhao XiaoWen, Bao JunJun, Hu Cui, Ding Hao, Xu ZhangWei, Liu XiaoChang, Mei Qiao, Xu JianMing. Clinical effect of endoscopic nasobiliary drainage in prevention of post- ERCP pancreatitis in patients with choledocholithiasis[J]. Journal of Clinical Hepatology, 2014, 30(8): 746-748. doi: 10.3969/j.issn.1001-5256.2014.08.012
[20]	Wang JiHeng, Gao Ge, Shi JiuJian. Causes and countermeasures of delayed hemobilia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2013, 29(9): 692-694. doi: 10.3969/j.issn.1001-5256.2013.09.015

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	周作玲，郭颖，杨娜. ERCP术后高淀粉酶血症发生情况及其影响因素分析. 中国医药导报. 2021(01): 103-106 .
2.	蒿玉敬，胡春霞，曹桂莉. 经内镜逆行胰胆管造影术后患者并发胰腺炎的危险因素分析及预防措施. 护理实践与研究. 2020(16): 21-23 .
3.	何应碧. 经内镜逆行性胰胆管造影术后鼻胆管引流术的价值分析. 齐齐哈尔医学院学报. 2019(01): 81-82 .
4.	陶涛，张明，张启杰，李明东，李桂花，唐丙喜，朱萧. 胰管支架预防胆总管结石ERCP术后并发症的临床研究. 中华全科医学. 2019(09): 1439-1442 .
5.	范秀平，黄晓利，李晓辉，黎涛. ERCP术后发生胰腺炎或高淀粉酶血症的相关因素分析. 河北医学. 2019(07): 1166-1169 .
6.	王艾，赵礼金. 经内镜逆行胰胆管造影术后胰腺炎的药物预防. 临床肝胆病杂志. 2017(01): 184-187 . 本站查看
7.	章杰，龙丹，王富华. 选择性胆管插管对经内镜逆行性胰胆管造影术后胰腺炎发生率和严重程度的影响. 中国医药科学. 2016(19): 175-178 .

Other cited types(6)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1911) PDF downloads(434)

Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography

DOI: 10.3969/j.issn.1001-5256.2016.01.022